MedTrace Logo

Seroprevalence of Brucella Antibodies in High-Risk Patients With Low Back Pain: A Case-Control Study

NCT07112677 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-08-08

No results posted yet for this study

Summary

The goal of this observational case-control study is to assess the presence of Brucella antibodies in patients with low back pain who are at high risk for brucellosis exposure, such as those with animal contact or consumption of unpasteurized dairy products. The main question it aims to answer is:

Is there a significant association between Brucella seropositivity and low back pain in high-risk individuals?

Researchers will compare patients with low back pain to age- and sex-matched healthy controls without back pain but with similar exposure risks, to see if Brucella antibodies are more frequent in the patient group.

Participants will:

Undergo a detailed clinical history and physical examination

Provide blood samples for serological testing using ELISA for Brucella IgG/IgM/IgA

Be evaluated for other symptoms such as fever, fatigue, and joint pain

Conditions

  • Brucellosis
  • Low Back Pain

Interventions

DIAGNOSTIC_TEST

Brucella Antibody Testing (ELISA)

Serological testing for Brucella antibodies using the SERION ELISA classic Brucella IgG/IgM/IgA kit (Institut Virion\\Serion GmbH, Würzburg, Germany). The test detects Brucella-specific IgG, IgM, and IgA antibodies in serum samples to assess current or past exposure. All samples were processed and interpreted according to the manufacturer's instructions. This diagnostic intervention was used for both the low back pain group and the control group.

Sponsors & Collaborators

  • Elham Ahmed Hassan

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07112677 on ClinicalTrials.gov